#United States #Salt Lake City #Sera Prognostics #Maternal Health #PreTRM Test

Sera Prognostics to Present at RBC Global Healthcare Conference

Sera Prognostics Inc., known as The Pregnancy Company®, is set to present at the highly anticipated RBC Global Healthcare Conference on May 21, 2025. The company's CEO, Zhenya Lindgardt, will engage attendees in a fireside chat to discuss the organization’s innovative contributions to maternal and neonatal health.

The event, scheduled for 9:30 AM to 9:55 AM ET, will be streamed live, allowing interested parties to participate virtually via a webcast accessible from the company’s investor relations page at www.sera.com.

Sera Prognostics is dedicated to enhancing the health outcomes of mothers and newborns through the development of cutting-edge pregnancy biomarker information. This is pivotal in helping healthcare providers make informed decisions that can significantly impact maternal and neonatal health. Their flagship offering, the PreTRM® Test, is designed to analyze the risk of spontaneous preterm birth for expectant mothers, thereby leading to earlier interventions for those identified as high-risk.

The Importance of Early Prediction in Pregnancy

Preterm births, defined as deliveries occurring before 37 weeks of gestation, remain a pressing concern in maternal and child health. Statistics indicate that over 10% of infants in the United States are born prematurely, leading to a series of complications that can affect long-term health outcomes.

According to the March of Dimes Report Card, the significant costs associated with premature birth-related healthcare were estimated at $25 billion annually in the United States in 2016 alone. Complications arising from preterm births can include chronic respiratory illnesses, intellectual disabilities, and more, which emphasize the necessity for early intervention and management strategies.

The PreTRM® Test offers a solution by providing healthcare providers with early, accurate, and individualized assessments of each patient’s risk for spontaneous preterm birth. This empowers physicians to tailor their care to the needs of the mother, resulting in better management strategies and potentially healthier outcomes for both mother and child.

Looking Ahead

As Sera Prognostics prepares for its presentation at the RBC Global Healthcare Conference, the anticipation surrounding their advancements in maternal health care continues to grow. The company’s commitment to introducing novel diagnostic tests reflects a strategic focus on addressing critical gaps in pregnancy care while also promoting proactive healthcare practices.

In addition to the PreTRM® Test, Sera has a robust pipeline aimed at predicting other pregnancy complications, showcasing its dedication to comprehensive maternal and neonatal health services. This commitment not only addresses the immediate healthcare needs but also aims to alleviate the broader economic impact of maternal and neonatal health complications.

As the conference approaches, the spotlight on Sera Prognostics will undoubtedly highlight the importance of innovative health solutions in shaping the future of pregnancy care, encouraging discussions that could lead to transformative changes in the industry. Stay tuned for further updates from the event and insights from the leadership at Sera Prognostics as they continue to lead the way in maternal and neonatal health advancements.